Abstract
Porin A (PorA), which determines the serosubtype of Neisseria meningitidis, is the main antigen of a candidate vaccine against serogroup B meningococci, which has been shown to induce high-avidity antibodies in children. We characterized the immune response of children after convalescing from meningococcal infection with a serosubtype P1.7-2,4 strain. Acute- and convalescent-phase sera of 21 children with meningococcal septic shock caused by strains with PorA subtype P1.7-2,4 were collected. The serum bactericidal antibody titers, IgG isotype distribution, and antibody avidity were measured. We determined whether the differences in avidity of anti–outer membrane vesicle antibodies were PorA specific. Serum bactericidal activity against H44/76 P1.7-2,4 was <4 in all convalescent sera. The IgG isotype distribution of the convalescent sera was dominated by IgG1, followed by IgG3, whereas no IgG2 or IgG4 was found. The geometric mean avidity index (GMAI) of convalescent sera measured against a strain with the identical subtype as the infective isolate was significantly higher than that against a strain with a heterologous PorA subtype or a PorA-negative mutant strain (57 versus 35 and 23%, respectively; p = 0.005 and p < 0.001). Geometric mean avidity titers were highest for P1.7-2,4, corresponding with the highest GMAI. The GMAI after invasive meningococcal disease was lower than after vaccination of healthy toddlers with a monovalent P1.7-2,4 outer membrane vesicle vaccine.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Abbreviations
- AI:
-
avidity index
- CI:
-
confidence interval
- GMAI:
-
geometric mean avidity index
- GMAT:
-
geometric mean avidity titer
- GMT:
-
geometric mean titer
- LPS:
-
lipopolysaccharide
- NaSCN:
-
sodium thiocyanate
- OMV:
-
outer membrane vesicle
- PorA:
-
porin A
- PorB:
-
porin B
- SBA:
-
serum bactericidal activity
References
Wedege E, Hoiby EA, Rosenqvist E, Bjune G 1998 Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial. Infect Immun 66: 3223–3231
Wedege E, Bolstad K, Wetzler LM, Guttormsen H 2000 IgG antibody levels to meningococcal porins in patient sera: comparison of immunoblotting and ELISA measurements. J Immunol Methods 244: 9–15
Pollard AJ, Galassini R, van der Voort EM, Booy R, Langford P, Nadel S, Ison C, Kroll JS, Poolman J, Levin M 1999 Humoral immune responses to Neisseria meningitidis in children. Infect Immun 67: 2441–2451
Pollard AJ, Levin M 2000 Production of low-avidity antibody by infants after infection with serogroup B meningococci. Lancet 356: 2065–2066
Bjune G, Hoiby EA, Gronnesby JK, Arnesen O, Fredriksen JH, Halstensen A, Holten E, Lindbak AK, Nokleby H, Rosenqvist E et al. 1991 Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338: 1093–1096
Boslego J, Garcia J, Cruz C, Zollinger W, Brandt B, Ruiz S, Martinez M, Arthur J, Underwood P, Silva W, Moran E, Hankins W, Gilly J, Mays J 1995 Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine 13: 821–829
de Moraes JC, Perkins BA, Camargo MC, Hidalgo NT, Barbosa HA, Sacchi CT, Landgraf IM, Gattas VL, Vasconcelos Hde G, Gral IM et al. 1992 Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 340: 1074–1078
de Kleijn E, van Eijndhoven L, Vermont C, Kuipers B, van Dijken H, Rumke H, de Groot R, van Alphen L, van den Dobbelsteen G 2001 Serum bactericidal activity and isotype distribution of antibodies in toddlers and schoolchildren after vaccination with RIVM hexavalent PorA vesicle vaccine. Vaccine 20: 352–358
Vermont CL, van Dijken HH, van Limpt CJ, de Groot R, van Alphen L, van Den Dobbelsteen GP 2002 Antibody avidity and immunoglobulin G isotype distribution following immunization with a monovalent meningococcal B outer membrane vesicle vaccine. Infect Immun 70: 584–590
Longworth E, Borrow R, Goldblatt D, Balmer P, Dawson M, Andrews N, Miller E, Cartwright K 2002 Avidity maturation following vaccination with a meningococcal recombinant hexavalent PorA OMV vaccine in UK infants. Vaccine 20: 2592–2596
Goldblatt D, Borrow R, Miller E 2002 Natural and vaccine-induced immunity and immunologic memory to Neisseria meningitidis serogroup C in young adults. J Infect Dis 185: 397–400
Joseph H, Miller E, Dawson M, Andrews N, Feavers I, Borrow R 2001 Meningococcal serogroup A avidity indices as a surrogate marker of priming for the induction of immunologic memory after vaccination with a meningococcal A/C conjugate vaccine in infants in the United Kingdom. J Infect Dis 184: 661–662
Richmond P, Borrow R, Goldblatt D, Findlow J, Martin S, Morris R, Cartwright K, Miller E 2001 Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J Infect Dis 183: 160–163
van der Voort ER, van der Ley P, van der Biezen J, George S, Tunnela O, van Dijken H, Kuipers B, Poolman J 1996 Specificity of human bactericidal antibodies against PorA P1.7,16 induced with a hexavalent meningococcal outer membrane vesicle vaccine. Infect Immun 64: 2745–2751
Guttormsen HK, Wetzler LM, Naess A 1993 Humoral immune response to the class 3 outer membrane protein during the course of meningococcal disease. Infect Immun 61: 4734–4742
Santos GF, Deck RR, Donnelly J, Blackwelder W, Granoff DM 2001 Importance of complement source in measuring meningococcal bactericidal titers. Clin Diagn Lab Immunol 8: 616–623
Welsch JA, Moe GR, Rossi R, Adu-Bobie J, Rappuoli R, Granoff DM 2003 Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J Infect Dis 188: 1730–1740
Welsch JA, Granoff DM 2004 Naturally acquired passive protective activity against Neisseria meningitidis Group C in the absence of serum bactericidal activity. Infect Immun 72: 5903–5909
Halstensen A, Lehmann AK, Guttormsen HK, Vollset SE, Bjune G, Naess A 1991 Serum opsonins to serogroup B meningococci after disease and vaccination. NIPH Ann 14: 157–165, discussion 166–167
Usinger WR, Lucas AH 1999 Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides. Infect Immun 67: 2366–2370
Lucas AH, Granoff DM 1995 Functional differences in idiotypically defined IgG1 anti-polysaccharide antibodies elicited by vaccination with Haemophilus influenzae type B polysaccharide-protein conjugates. J Immunol 154: 4195–4202
Acknowledgements
We thank René Kornelisse and Ester de Kleijn for collecting patient serum samples and Wendy Keijzers for sequencing part of the PorA gene of the patient isolates.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Vermont, C., van Dijken, H., de Groot, R. et al. Porin A—Specific Antibody Avidity in Patients Who Are Convalescing from Meningococcal B Disease. Pediatr Res 58, 149–152 (2005). https://doi.org/10.1203/01.PDR.0000156372.13569.08
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1203/01.PDR.0000156372.13569.08
